Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05647954
Study type Interventional
Source Taizhou Hanzhong biomedical co. LTD
Contact Jun Guo, MD
Phone 861088196348
Email guoj307@126.com
Status Not yet recruiting
Phase Phase 3
Start date December 31, 2022
Completion date June 30, 2025